Sorry, you need to enable JavaScript to visit this website.
Home Science Areas of Focus Oncology

Over the past decade, we’ve taken bold new approaches to translate scientific research into effective medicines for people living with cancer. Now, we’re working tirelessly to develop a new generation of breakthroughs across multiple cancers and tumor types.

  • Worldwide, breast cancer is the most common invasive cancer, with more than 2.2 million impacted annually. Metastatic breast cancer (mBC), the most advanced stage of breast cancer in which the cancer has spread beyond the breast to other parts of the body (i.e., organs, bones), remains an incurable disease. As a result of earlier screening, increased awareness, and better treatments, breast cancer deaths have continued to decrease in older women. From 2013 to 2018, the death rate went down by 1% per year. 

  • The genitourinary (GU) tract is comprised of urinary, reproductive and adrenal system organs. Organs of the genitourinary tract include the prostate (males only), kidneys and bladder. GU cancers are pervasive and notoriously hard to treat, despite available therapies. Each person’s cancer behaves differently, requiring a tailored, individualized approach for each individual. 

  • Blood cancers strike ruthlessly at any age. Some come fast and take lives within weeks or months. Others develop in the bones and blood over time, requiring intense and aggressive treatment interventions that are traumatic, emotionally overwhelming, and expensive. More than 1 million people worldwide were diagnosed with a blood cancer in 2020, representing almost 6% of all cancer diagnoses globally. In 2020, more than 700,000 people worldwide died from a form of blood cancer. 


  • Lung cancer remains the leading cause of cancer-related death among men and women globally, and the global five-year survival rate at 17.8 percent is much lower than leading cancers. Lung cancer is notoriously difficult to treat due to the heterogeneous nature of the disease, variability in testing rates and the onset of drug resistance. These challenges necessitate an individualized approach to treatment, ensuring people with lung cancer receive the right drug at the right time.

  • Worldwide, colorectal cancer is the third most common type of cancer in men, and the second most common in women, with approximately 1.8 million new diagnoses in 2018. In the U.S. alone, an estimated 147,950 people will be diagnosed with cancer of the colon or rectum in 2020, and approximately 53,000 are estimated to die of their disease each year. 

  • Though melanoma skin cancer is much less common (1%) than some other types of skin cancers, it causes the vast majority of skin cancer deaths. It is considered more dangerous because it’s much more likely to invade nearby tissue and spread to other parts of the body if not caught and treated early when it is most likely to be cured. 

Cancer is not a singular disease, so our approach to treating it must be every bit as adaptive and nimble as the disease itself. Each day, our scientists get closer to discovering breakthroughs that will save lives.

Cancer is one of the most complex diseases known to mankind. Our scientists explain some of the biggest challenges they’re looking to overcome in cancer research. 

Our Centers for Therapeutic Innovation collaborates with academic institutions and investigators to push forward great science, using the depth and breadth of the Pfizer enterprise to accelerate concepts into viable therapies with breakthrough potential for patients.

Find Out More About CTI

Our Research & Development colleagues are working at sites across the globe to support our product pipeline.

Details from major Research & Development locations are listed below.

AndoverAndover, Massachusetts
A 70-acre site that combines state-of-the-art R&D facilities with flexible, multi-product manufacturing capabilities
boulderBoulder, Colorado
An expert in small molecule drug discovery with a focus on developing innovative cancer therapeutics
CambridgeCambridge, Massachusetts
Global headquarters for our Center for Therapeutic Innovation (CTI), which has established locations in New York City, San Diego, and San Francisco
GrotonGroton, Connecticut
Where nearly every one of our products are, in part, developed
lajollaLa Jolla, California
Powerfully reinforcing the company's presence in the global biotechnology industry
Pearl RiverPearl River, New York
The primary location for our company’s global Vaccine Research and Development work
SandwichSandwich, UK
Home of the Pharmaceutical Sciences and Global Regulatory Affairs groups
Approved_ChesterfieldPicture_2022_External_450x600.jpgSt. Louis, MO
A 295,000 sq ft. site, contributes to advancing Pfizer’s biotherapeutic, vaccine, and gene therapy portfolio.

Revolutionary medicines have the power to enrich and extend life across many disease areas. Explore our latest innovations.

Rare Disease
View All Rare Disease

Explore all of our disease and condition-related resources to learn more about your diagnosis and treatment options. 

Gene Therapy
Duchenne Muscular Dystrophy 
Gaucher Disease
Growth Hormone Deficiency 
Sickle Cell 
Transthyretin Amyloidosis 

Internal Medicine
View All Internal Medicine

We’re developing therapies to treat, slow, or prevent disease progression and improve the quality of life for patients with obesity, type 2 diabetes, and cardiovascular and kidney diseases. 

Inflammation & Immunology
View All Inflammation & Immunology

We look for treatments that provide more than just symptom relief, in order to address the root cause of chronic inflammatory diseases at a molecular level

View All Vaccines

Vaccines are the single most important innovation in the science of health to significantly reduce the threat of diseases that were once widespread and oftentimes fatal. 

Pipeline & Clinical Trials 

View All Oncology

Cancer treatment needs to be transformed across the entire landscape to significantly improve the lives of cancer patients worldwide.

Biology into medicine
Global Impact

Anti Infectives
View All Anti Infectives

Anti-infectives are medicines that work to prevent or treat infections, including antibacterials, antivirals, antifungals, and antiparasitic medications. 

Antimicrobial Resistance 
AMR Prevention 
Antimicrobial Surveillance 
Antimicrobial Stewardship 
Our Commitment as a Global Leader 
Environmental Protection 

  • 00Phase 1
  • 00Phase 2
  • 00Phase 3
  • 00Registration
  • 00Total

Meet the people behind our medicines. Our experts make discoveries that give the world cutting-edge treatments for conditions that span the range from the common cold to rare diseases.

Media Name: jean_beebe300x170.jpg

Vice President, Clinical Portfolio Leader, I&I Research Unit

Media Name: seng_cheng300x170.jpg

Senior Vice President & Chief Scientific Officer, Rare Disease

Media Name: nanette_cocero300x170.jpg

Global President, Vaccines, Pfizer Biopharmaceuticals Group

Media Name: Olivier_Dirat_300x170px.jpg

Associate Research Fellow and Group Leader, Chemical Development Active Pharmaceutical Ingredients

Media Name: jeff_settleman300x170.jpg

Chief Scientific Officer

Media Name: k_beaverson300x170.jpg

Executive Director, Patient Advocacy Lead

Media Name: Kendra_Bence_300x170px.jpg

Executive Director, Metabolism

Media Name: binks300x170.jpg

Vice President, Clinical Research

Media Name: Julie_Brooks_300x170px.jpg

Postdoctoral Fellow

Media Name: christian_czech300x170.jpg

Senior Director, Biology and Nice Site Lead

Media Name: jeremy_d_gale300x170.jpg

Vice President and Clinical Portfolio Leader

Media Name: grimwood300x170.jpg

Executive Director, Head of Portfolio, Strategy & Operations

Media Name: GRUBER BILL 300x170.jpg

Senior Vice President of Pfizer Vaccine Clinical Research and Development


Chief Medical Officer and Head of Worldwide Medical & Safety

Media Name: K-Jansen_300x170px.jpg

Senior Vice President, Head of Vaccine Research and Development

Luis Jodar bio pic

SVP & Chief Medical Officer, Pfizer Vaccines

Media Name: Nicholas_Kitchin_300x170px.jpg

Senior Director

Media Name: Jennifer_Lafontaine_300x170px.jpg

Senior Director, Oncology Medicinal Chemistry Synthesis and Analytical Group

Media Name: LaRosa_21_300x170.jpg

Vice President, Head of Scientific Research

Media Name: Carolyn_Leverett_300x170px.jpg

Principal Scientist, Oncology Medicinal Chemistry

Media Name: clark_pan_300x170.jpg

Vice President, Gene Therapy and Discovery Biology


Vice President, Rare Neurology and Discovery Biology


Senior Vice President and Chief Scientific Officer, Internal Medicine Research Unit

Media Name: Ravi_Shanker_300x170px.jpg

Senior Research Fellow, Pharmaceutical Sciences

Media Name: Bruce_Thompson_300x170px.jpg

Sr. Principal Scientist, Biotherapeutics Pharmaceutical Sciences

Media Name: Fabien_Vincent_300x170px.jpg

Associate Research Fellow, Hit Discovery and Lead Profiling

Media Name: thomas_a_wynn300x170.jpg

Vice President, Discovery

Media Name: bei_zhang_300x170.jpg

Vice President, Metabolic Research

Learn more about the process of joining a clinical trial and find a trial near you.

Go to Pfizer Clinical Trials Site